Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Neurol. Dec 28, 2013; 3(4): 144-147
Published online Dec 28, 2013. doi: 10.5316/wjn.v3.i4.144
Published online Dec 28, 2013. doi: 10.5316/wjn.v3.i4.144
Antiplatelet strategy for acute ischemic stroke: A mini review
Zhong-He Zhou, Hui-Sheng Chen, Department of Neurology, General Hospital of Shen-Yang Military Region, Shenyang 110840, Liaoning Province, China
Author contributions: Zhou ZH contributed to writing the manuscript; Chen HS contributed to designing and revising the manuscript.
Supported by The Science and Technology Project Plan of Liao Ning Province, No. 2011225021; the Key Project of the National 12th Five-Year Research Program of China, No. 2012ZX09303016-002
Correspondence to: Hui-Sheng Chen, MD, Professor, Department of Neurology, General Hospital of Shen-Yang Military Region, 83 Wenhua Road, Shenyang 110840, Liaoning Province, China. chszh@aliyun.com
Telephone: +86-24-28897511 Fax: +86-24-28856448
Received: July 2, 2013
Revised: August 9, 2013
Accepted: September 14, 2013
Published online: December 28, 2013
Revised: August 9, 2013
Accepted: September 14, 2013
Published online: December 28, 2013
Core Tip
Core tip: Patients with acute ischemic stroke have a high risk of deterioration in the 48-72 h after symptom onset. Although thrombolysis is an effective method, most patients are excluded due to the limit of strict indications. Early antiplatelets are recommended for most patients. However, the question remains unclear whether another effective and safe antiplatelet strategy for the treatment of acute ischemic stroke exists. Growing evidence shows that combination antiplatelets may be superior to mono antiplatelets in the treatment of acute ischemic stroke.